CRG

CRG, headquartered in Houston, United States, stands as a prominent and pioneering investment firm dedicated exclusively to the healthcare sector. Since its inception, CRG has carved out a unique niche by providing innovative growth capital solutions, primarily to commercial-stage biopharmaceutical and medical device companies. Their approach distinguishes them from traditional venture capital or private equity firms, focusing on structured finance that leverages the intellectual property and revenue streams of established healthcare assets. This strategy allows companies to access significant capital without the substantial equity dilution often associated with conventional funding rounds, making CRG a crucial partner for firms looking to scale their operations and commercialize their products.

The firm's core investment strategy revolves around offering senior secured loans and royalty financings. This method is particularly appealing to companies with approved products or those nearing commercialization, as it provides flexible, non-dilutive, or minimally dilutive capital. CRG's expertise lies in evaluating the underlying value of intellectual property, clinical data, and commercial potential, enabling them to structure bespoke financing solutions that align with a company's specific growth trajectory and capital needs. Their deep understanding of the regulatory landscape and market dynamics within healthcare further solidifies their position as a strategic financial partner.

Over the years, CRG has demonstrated a significant commitment to the healthcare industry, having deployed over $4.5 billion in capital since 2003. This substantial investment has supported more than 95 healthcare companies, facilitating the development and commercialization of numerous life-changing therapies and medical technologies. CRG typically invests between $20 million and $200 million in a single transaction, reflecting their capacity to support a wide range of capital requirements for growth-oriented healthcare enterprises. Their consistent focus on intellectual property-backed assets and commercial-stage companies underscores their role in accelerating innovation and market penetration within the global healthcare ecosystem.